Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Accounts Payables (2021 - 2025)

Bioregenx has reported Accounts Payables over the past 5 years, most recently at $615990.0 for Q4 2025.

  • For Q4 2025, Accounts Payables rose 44.1% year-over-year to $615990.0; the TTM value through Dec 2025 reached $615990.0, up 44.1%, while the annual FY2025 figure was $615990.0, 44.1% up from the prior year.
  • Accounts Payables for Q4 2025 was $615990.0 at Bioregenx, up from $459652.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $615990.0 in Q4 2025 and troughed at $11996.0 in Q4 2021.
  • A 5-year average of $270444.8 and a median of $306276.0 in 2023 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: soared 1784.61% in 2024 and later crashed 80.57% in 2025.
  • Year by year, Accounts Payables stood at $11996.0 in 2021, then skyrocketed by 64.4% to $19721.0 in 2022, then skyrocketed by 1125.57% to $241695.0 in 2023, then skyrocketed by 76.87% to $427478.0 in 2024, then skyrocketed by 44.1% to $615990.0 in 2025.
  • Business Quant data shows Accounts Payables for BRGX at $615990.0 in Q4 2025, $459652.0 in Q3 2025, and $568799.0 in Q2 2025.